Crystal Lake-based AptarGroup Inc. has acquired two pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined value of approximately $50 million. The acquisitions are part of Aptar's strategy to broaden its portfolio of services.
Both acquisitions bring complementary, value-added and differentiated analytical, testing and development services for all stages of drug development and commercialization. The expanded services platform will enable Aptar Pharma to collaborate earlier with customers to support their complex drug formulations and delivery requirements as they face increasingly competitive and regulated markets.
Nanopharm, located in Newport, U.K., is a provider of orally inhaled and nasal drug product design and development services. Gateway Analytical, located outside Pittsburgh, provides particulate detection and predictive analytical services to customers developing injectable medicines.
The companies’ results will be included in the Pharma segment and the transactions are not expected to be dilutive to Aptar’s earnings in 2019.
